Altimmune
ALT
Altimmune (ALT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.12
- EPS estimate
- −$0.14
- EPS surprise
- +11.44%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.14 | −$0.12 | +11.44% | $0.00 | SEC |
| Q1 2026 | May 13, 2026 | −$0.24 | −$0.18 | +25.71% | $0.00 | SEC |
| Q4 2025 | Mar 5, 2026 | −$0.23 | −$0.27 | −15.38% | $26,000.00 | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.27 | −$0.21 | +22.82% | $5,000.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.34 | −$0.27 | +19.69% | $5,000.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.35 | −$0.26 | +26.12% | $5,000.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.33 | −$0.33 | +0.75% | $5,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.36 | −$0.32 | +10.26% | $5,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.35 | −$0.35 | −0.40% | $5,000.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.37 | −$0.34 | +8.11% | $5,000.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$0.46 | −$0.54 | −18.68% | $37,000.00 | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.45 | −$0.39 | +13.81% | $362,000.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.47 | −$0.32 | +31.18% | $6,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.48 | −$0.40 | +16.67% | $21,000.00 | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.50 | −$0.43 | +14.24% | −$110,000.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.51 | −$0.48 | +4.95% | $2,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.50 | −$0.42 | +16.00% | $8,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.59 | −$0.44 | +25.42% | $32,000.00 | SEC |
| Q4 2021 | Mar 15, 2022 | −$0.66 | −$0.57 | +13.64% | $3.3M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.45 | −$0.81 | −81.74% | $157,559.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Altimmune (ALT) last report earnings?
Altimmune last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did ALT beat earnings estimates?
Yes. Altimmune reported EPS of −$0.12 for Q2 2026 against a −$0.14 estimate — a 11.44% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.